跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ULTOMIRIS ravulizumab rch 10 mg/mL concentrated solution for intravenous infusion vial - TGA Drug Approval Details
Approvals
/
TGA
/
ULTOMIRIS ravulizumab rch 10 mg/mL concentrated solution for intravenous infusion vial
Approved
STANDARD
ULTOMIRIS ravulizumab rch 10 mg/mL concentrated solution for intravenous infusion vial
Alexion Pharmaceuticals Australasia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
fc6c3d684d2fc71d
Company
Alexion Pharmaceuticals Australasia Pty Ltd
Type
Standard
Approval Details
Approval Id
fc6c3d684d2fc71d
Product Name
ULTOMIRIS ravulizumab rch 10 mg/mL concentrated solution for intravenous infusion vial
Artg Id
311926
Artg Name
ULTOMIRIS ravulizumab rch 10 mg/mL concentrated solution for intravenous infusion vial
Sponsor
Alexion Pharmaceuticals Australasia Pty Ltd
Company Detail Path
/organization/alexion-pharmaceuticals-australasia-pty-ltd
Artg Date
2019-10-17
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
fc6c3d684d2fc71d
Type
Standard
Back to TGA Approvals
